ESH Video

2nd How to Diagnose and Treat: Acute Leukaemia

2nd How to Diagnose and Treat: Acute Leukaemia
June 30 - July 02, 2020 - , ONLINE CONFERENCE
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock


CONFERENCE UPDATE: novel coronavirus (COVID-19)

2nd How to Diagnose and Treat Acute Leukaemia conference: MOVING ONLINE!

June 30 – July 2, 2020

(Initially March 13-15, 2020) Budapest, Hungary
Chairs: Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock


Due to continuing COVID-19 related challenges and uncertainties, ESH has decided to transform the event into a virtual conference, on the same dates.
ESH wishes to support the healthcare community in this challenging period. Registration in this virtual meeting is offered to you free of charge. Participants who have already paid their registration fee, will be reimbursed.

We hope that you will be interested in joining us for this ESH e-Conference on Acute Leukaemias, click here to visit the e-Conference platform!

Stay Safe!
The ESH Team


ESH 2nd How to Diagnose and Treat:
Acute Leukaemia
Chairs: Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

Programme Summary

European School of Haematology (ESH) How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management on the basis of presentation, analysis and discussion of real clinical cases. One major objective is to promote interaction between the speakers and participants.

Novel and still evolving insights into the biology and diagnosis of acute leukaemias, including acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), is offering new therapeutic options with recent drug approvals to treat newly-diagnosed as well as relapsed/refractory disease.

The programme of this “2nd How to Diagnose and Treat: Acute Leukaemia” meeting will deal with integration of genomic analysis and cutting-edge technics in routine diagnosis, gene mutation-based therapies and new standard treatment algorithms, allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.

Posters and Brief Oral Communications:

Registered participants are invited to submit their Biology and Clinical abstracts, and Clinical Cases. Selected abstracts will be presented as posters; selected Clinical Cases will be presented as brief oral communications or posters.


This meeting will be valuable for you if you are looking for:

  • A cutting-edge scientific programme – from basic science to clinical and therapeutic applications and perspectives
  • Multiple opportunities for scientific interaction with an international faculty of distinguished experts
  • An emphasis on critical discussion

 The meeting will provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field.

This meeting will be of interest to:

  • Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
  • Junior biologists and clinicians (MD, PhD) 
  • Clinical residents still in-training
  • Allied health care professionals

Learning objectives:

  • Learn about the modern sets of diagnosis tests needed to optimally manage patients with AML and ALL
  • Review and hierarchize the new treatment standards that available to AML and ALL patients for front-line and for salvage therapy
  • Understand the value and role of leukaemic stem cell targeting and measurable residual disease (MRD) levels to stratify acute leukaemia therapy
  • Gain insight into emerging mechanisms associated with clinical resistance and leukaemia escape
  • Understand the effects and place of new immunotherapies with respect to standard or new HSCT procedures

Topics :

  • Rare subsets of acute leukaemia
  • Tracking leukaemic stem cells (LSCs)
  • Routing diagnosis gene expression and mutational profiling
  • Addition of a 3rd agent to frontline 7+3
  • Allogeneic hematopoietic stem cell transplantation (HSCT)
  • Immunotherapy for acute leukaemia

The programme will include:

  • Plenary Sessions
  • Interactive Case Presentations
  • Roundtables
  • Panel Discussions
  • Debates
  • Poster Presentations
  • Voting boxes



Participants will be joining us from all over the world and from different time zones. We want to make sure that everyone has access to the full scientific programme at a convenient hour. For this reason, registration allows you to join both the LIVE PROGRAMME and the PROGRAMME ON DEMAND. The Virtual platform will remain open from June 20 until July 12 so that you can view and review the programme’s full scientific content at times convenient to you.

June 30-July 2, CEST time.
It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions, voting and Q&A periods, and Mentored Poster Walks.  It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period. Consult the LIVE PROGRAMME HERE

June 20 – July 12
Access the pre-recorded components of the scientific programme as of June 20. The meeting’s live, interactive components will be recorded real time and will progressively enrich the Programme on Demand. Access to the meeting’s full scientific content will remain open on the virtual platform until July 12. Consult the PROGRAMME ON DEMAND HERE.

June 30 – July 12

The Poster Hall will also remain open until July 12.
The Mentored Poster Walk scheduled in the LIVE PROGRAMME will also become available in the PROGRAMME ON DEMAND.

Symposia organized independently by our corporate partners in conjunction with the ESH meeting will also be available both Live and On Demand as described above, from June 20 until July 12.

June 20 – July 12
We invite you to visit the e-Exhibition area as of June 20 . Our corporate partners will be pleased to welcome and chat with you.


Abstract submission









Conference Moving online.

Visit the e-Conference platform

Corporate partners

With the support of*



Major Conference Partners




Level 2 Conference Partners


Supporting Partner 



*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.





Educational Grants

ESH gratefully acknowledges

Celgene-BMS logo

for providing a Medical Education Grant

towards this independent programme.


The registration for the “2nd How to Diagnose and Treat Acute Leukaemia” e-Conference is free.

Register Here